CEL-SCI is a clinical-stage biotechnology company. The company is focused on the development of the following product candidates and technologies: Multikine, an investigational immunotherapy under development for the treatment of certain head and neck cancers; and Ligand Epitope Antigen Presentation System (LEAPS) technology, with two investigational therapies, CEL-2000 and CEL-4000, vaccine product candidates under development for the treatment of rheumatoid arthritis, and LEAPS-H1N1-DC, a product candidate under development for the potential treatment of pandemic influenza in hospitalized patients.

Chimerix is a biopharmaceutical company focused on developing medicines for patients living with cancer and other serious diseases. The company's two clinical-stage development programs are dociparstat sodium, a potential glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of several key proteins implicated in the retention and viability of AML blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir, an oral antiviral in development as a medical countermeasure for the treatment of smallpox.

Fulcrum is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases.

Golub Capital BDC is registered as an externally managed, closed-end, non-diversified management investment company. The company makes investments primarily in one stop (a loan that combines characteristics of first lien senior secured loans and second lien or subordinated loans) and other senior secured loans of middle-market companies that are, in most cases, sponsored by private equity firms. The company's investment objective is to generate existing income and capital appreciation by investing primarily in one stop and other senior secured loans of United States middle-market companies.

Molecular Templates is a clinical-stage company focused on the discovery and development of biologic therapeutic for cancer and other serious diseases. The company utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies (ETBs). The company is developing ETBs for various targets, including CD20, CD38, HER2, PD-L1, CTLA-4, SLAMF-7, and CD45. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of various myeloma. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.

ServiceSource International is engaged in outsourced customer success and revenue growth solutions. The company's solutions span the lifecycle of its clients' customers, from landing new customers (Co. provides lead generation, inside sales, and outsourced sales operations services), adoption (Co. provides customer onboarding and customer success management services), expansion (Co. provides cross-sell and upsell, warranty conversion, account-based marketing and channel recruitment and enablement) and renewals (Co. provides renewals management services, including the sale of maintenance and support service contracts for the products used by its clients' end-users).